Valuation: Amplia Therapeutics Limited

Market Cap 45.68M 31.42M 28.18M 25.75M 23.51M 44.29M 2.95B 310M 124M 1.58B 118M 115M 4.97B P/E 2027 *
-3.87x
P/E 2028 * -12.7x
Enterprise Value 27.78M 19.11M 17.14M 15.66M 14.3M 26.94M 1.8B 189M 75.27M 958M 71.72M 70.18M 3.03B EV / Sales 2027 *
-
EV / Sales 2028 * 2.35x
Free-Float
90.48%
Yield 2027 *
-
Yield 2028 * -
1 day-1.11%
1 week+5.95%
Current month+5.95%
1 month-22.61%
3 months-40.67%
6 months-34.07%
Current year-40.67%
1 week 0.08
Extreme 0.081
0.09
1 month 0.08
Extreme 0.076
0.11
Current year 0.08
Extreme 0.076
0.28
1 year 0.08
Extreme 0.076
0.28
3 years 0.05
Extreme 0.049
0.42
5 years 0.05
Extreme 0.049
0.42
10 years 0.04
Extreme 0.045
18.3
Manager TitleAgeSince
Chief Executive Officer - 05/12/2022
Director of Finance/CFO - 01/10/2021
Chief Tech/Sci/R&D Officer - 12/05/2025
Director TitleAgeSince
Director/Board Member 70 02/09/2015
Chairman - 25/05/2018
Chairman - 30/06/2026
Date Insider Type Main position Quantity % Market Cap. Importance
8/9/25 Exercice

Chairman

750,000 0.1933%
8/9/25 Free

Founder

447,000 0.1152%
8/9/25 Exercice

Director

535,000 0.1379%
Change 5-day change 1-year change 3-year change Capi.($)
-1.11%+5.95%-25.83%+12.66% 31.42M
-4.83%+3.51%+53.62%+61.75% 65.94B
-1.34%+2.98%+24.79%+100.18% 56.53B
+0.02%+1.07%+10.63%+76.66% 56.88B
+5.09%+9.89%+22.45%+107.48% 46.49B
+2.62%+1.68%+28.91%+37.01% 44.8B
+8.24%+0.51%+213.26%+792.66% 41.59B
-1.86%+10.13%+26.82%+53.22% 35.35B
-2.97%-9.84%+88.86%+76.17% 33.29B
-2.18%+7.06%+36.06%-4.95% 24.92B
Average +0.17%+3.52%+47.96%+131.29% 40.58B
Weighted average by Cap. +0.21%+3.40%+53.11%+142.95%

Financials

2027 *2028 *
Net sales - 9.5M 6.53M 5.86M 5.35M 4.89M 9.21M 614M 64.54M 25.74M 328M 24.52M 23.99M 1.03B
Net income -11.6M -7.98M -7.15M -6.54M -5.97M -11.25M -750M -78.81M -31.43M -400M -29.94M -29.3M -1.26B -4.1M -2.82M -2.53M -2.31M -2.11M -3.97M -265M -27.86M -11.11M -141M -10.58M -10.36M -446M
Net Debt -17.9M -12.31M -11.04M -10.09M -9.21M -17.35M -1.16B -122M -48.49M -617M -46.2M -45.21M -1.95B -23.4M -16.09M -14.43M -13.19M -12.04M -22.68M -1.51B -159M -63.39M -807M -60.4M -59.1M -2.55B
Projected Income Statement - Annual - Amplia Therapeutics Limited
Logo Amplia Therapeutics Limited
Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development company. The Company is focused on developing proprietary, orally available, small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. Its pipeline includes narmafotinib (AMP945) and AMP886. Its lead drug candidate, narmafotinib, is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). The Company’s second pipeline drug, AMP886, inhibits FAK and inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is being evaluated in preclinical models of cancer. Its cancer Program is directed at using its FAK inhibitors to block FAK activity in the cancer cells and the surrounding tissue.
Employees
-
Date Price Change Volume
06/11/26 $0.0890 -1.11% 706,919
05/11/26 $0.0900 +1.12% 1,209,884
04/11/26 $0.0890 +5.95% 531,430
03/11/26 $0.0840 0.00% 462,156
02/11/26 $0.0840 0.00% 736,376
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0890AUD
Average target price
0.4200AUD
Spread / Average Target
+371.91%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Amplia Therapeutics Limited